Dendritic cells: On the move from bench to bedside

Nature Medicine

Volumn 7, Issue 7, 2001, Pages 761-765

  Nestle, Frank O ^a   Banchereau, Jacques ^b   Hart, Derek ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

AUTOIMMUNE DISEASE; CANCER; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL MATURATION; DENDRITIC CELL; DRUG MONITORING; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; VACCINATION;

CANCER VACCINES; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; NEOPLASMS; QUALITY CONTROL;

EID: 0034918104     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/89863     Document Type: Review

References (44)

1. Dendritic cells and the control of immunity
2. Dendritic cell based therapy of cancer
3. Phenotypic characterization of dendritic cells
4. Immunotherapy of cancer with dendritic-cell-based vaccines
5. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
6. Dendritic cell vaccines for cancer immunotherapy
7. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
8. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
9. Dendritic cells in cancer immunotherapy
10. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α
11. Proliferating dendritic cell progenitors in human blood
12. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo
13. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?
14. 7th leucocyte differentiation antigen workshop dendritic cells section summary
15. Murine epidermal Langerhans cells mature into potent allostimulatory dendritic cells in vitro
16. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
17. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
18. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase 2 prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
19. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
20. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
21. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
22. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
23. CD91: A receptor for heat shock protein gp96
24. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
25. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells
26. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
27. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes
28. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration
29. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines
30. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy
31. Migration of human dendritic cells after injection in patients with metastatic malignancies
32. Dendritic cells injected via different routes induce immunity in cancer patients
33. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery
34. A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
35. A method for the production of cryopreserved aliquots of antigen- preloaded, mature dendritic cells ready for clinical use
36. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
37. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-Cell responses against antigens expressed by primary and metastatic tumors
38. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells
39. MUC1 epithelial mucin - Expression by normal haematopoietic cells
40. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
41. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
42. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases
43. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
44. Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma